Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(24):1970-1971; doi:10.1093/jnci/92.24.1970
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Vastag, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vastag, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 24, 1970-1971, December 20, 2000
© 2000 Oxford University Press

NEWS

Effect of Mifepristone Approval On Research Remains to Be Seen

Brian Vastag

When the U.S. Food and Drug Administration awarded final marketing approval for mifepristone (RU-486) in September, women’s rights activists rejoiced that the drug, long available elsewhere in the world, would finally provide U.S. women with a nonsurgical abortion option. Lost in the hubbub was mifepristone’s potential as an anticancer agent.



View larger version (131K):
[in this window]
[in a new window]
  		Mifepristone is distributed in the United States by Danco Laboratories and marketed as MifeprexTM.

 
Whether such research accelerates remains to be seen. But with one large barrier to access now gone, several researchers voiced optimism that clinical work with the drug—mainly in ovarian, breast, and brain cancer—will take off. Preclinical work in prostate cancer also shows promise, according to several scientists.

The cause for such optimism? Mifepristone blocks cell surface receptors for the hormone progesterone; these . . . [Full Text of this Article]

The Bush Ban


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?